you are here: HomeNewsBusiness

Serum Institute's Adar Poonawalla exits Panacea Biotec, sells entire stake for Rs 118 crore

The shares were picked by Serum Institute of India (SII). As per BSE block deal data, Poonawalla sold 31,57,034 scrips he held in the firm at a price of Rs 373.85 per share, taking the total deal value to Rs 118.02 crore.

May 17, 2021 / 09:50 PM IST
Serum Institute India (SII) CEO Adar Poonawalla (Image: Twitter/@adarpoonawalla)

Serum Institute India (SII) CEO Adar Poonawalla (Image: Twitter/@adarpoonawalla)

Serum Institute of India CEO Adar Poonawalla on Monday offloaded his entire stake in Panacea Biotec amounting to 5.15 per cent shareholding of the firm for Rs 118 crore, through an open market transaction.

The shares were picked by Serum Institute of India (SII). As per BSE block deal data, Poonawalla sold 31,57,034 scrips he held in the firm at a price of Rs 373.85 per share, taking the total deal value to Rs 118.02 crore.

Threats from powerful, head will be chopped off if I comment on elections or Kumbh: SII CEO Adar Poonawalla

The shares were picked by SII at the same price, through a separate transaction. As per shareholding data for March 2021 quarter, both Poonawalla and SII were public shareholders in the firm and held 5.15 per cent and 4.98 per cent stake in Panacea, respectively.

Shares of Panacea Biotec on Monday ended at Rs 384.9 apiece, 1.16 per cent higher over the previous close. Separately, Sarda Mines sold shares worth Rs 227.66 crore in Jindal Steel and Power Ltd.

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Over 52.74 lakh scrips were offloaded at the price of Rs 431.62 apiece. Jindal Steel and Power stock on Monday ended 4.65 per cent higher at Rs 436.55.
PTI

stay updated

Get Daily News on your Browser
Sections